Glukoza Fresenius (Glucose Monohydrate)

Glukoza Fresenius is indicated for several clinical situations where rapid carbohydrate delivery or fluid balance is needed.

• Treatment of acute hypoglycemia in patients unable to take oral glucose.
• Component of parenteral nutrition regimens for patients lacking enteral intake.
• Intravenous fluid and electrolyte replacement when additional carbohydrate calories are required.
• Support during peri‑operative care to maintain blood glucose stability.
• Dilution medium for certain intravenous medications that require a glucose‑based carrier.
• Adjunct in emergency resuscitation protocols where glucose supplementation is part of the therapeutic algorithm.

Glukoza Fresenius may be associated with transient physiological changes after intravenous infusion; most reactions are mild and self‑limiting, while rare events can be clinically significant.

Common

• Mild hyperglycemia that usually resolves with routine glucose monitoring and does not require treatment.
• Transient rise in serum sodium from the solution’s electrolytes, typically normalizing within a few hours.
• Local irritation or erythema at the infusion site, appearing as mild redness or discomfort.
• Nausea or mild headache during rapid infusion, generally subsiding after the dose is completed.

Serious

• Severe hyperglycemia that may cause osmotic diuresis and require insulin therapy.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis, needing immediate medical care.
• Electrolyte imbalance, especially hypernatremia, when large volumes are infused rapidly, potentially leading to neurologic signs.
• Fluid overload in patients with cardiac or renal impairment, which can precipitate pulmonary edema.

When using Glukoza Fresenius, clinicians should assess patient-specific factors and monitor parameters to minimize risks associated with intravenous glucose administration.

• Verify blood‑glucose level before infusion and adjust rate to avoid excessive hyperglycemia.
• Assess renal and cardiac function, especially in patients at risk for fluid overload.
• Use appropriate infusion sets and filter to prevent particulate contamination.
• Monitor serum electrolytes, particularly sodium, during and after prolonged administration.
• Document any allergic history; avoid use in patients with known hypersensitivity to glucose solutions.
• Adjust infusion rate in pediatric or elderly patients, as they may have altered glucose metabolism.

Glukoza Fresenius can interact with other intravenously administered agents; awareness of potential interactions helps maintain therapeutic safety.

Avoid

• Co‑administration with high‑dose insulin infusions without glucose monitoring, which may precipitate severe hypoglycemia.
• Simultaneous infusion of hypertonic saline solutions that could exacerbate hypernatremia.

Use with caution

• Concurrent use of diuretics that affect electrolyte balance; monitor sodium and fluid status closely.
• Administration alongside other carbohydrate‑containing fluids, to prevent cumulative hyperglycemia.
• Use in patients receiving total parenteral nutrition formulas, adjusting overall glucose load as needed.
• When combined with vasopressor therapy, monitor hemodynamic response as rapid glucose shifts can influence blood pressure.